SERB Pharmaceuticals acquiert l’Aurlumyn (Iloprost IV) auprès de CiVi Biopharma Holdings Inc.

Mayer Brown a conseillé SERB Pharmaceuticals dans le cadre de la structuration de l’acquisition de Aurlumyn® (iloprost IV) auprès de CiVi Biopharma Holdings Inc.SERB Pharmaceuticals a…

This content is for members only.
Join Now
Already a member? Log in here

Author: Georgio Naffaa

This content is for members only.
Join Now
Already a member? Log in here